BioCentury | May 18, 2020
Finance

$65M round positions SQZ Biotech for potential IPO, 2021 catalysts

SQZ Biotech is adding at least one experienced crossover investor to what could be its last private financing ahead of catalysts expected late this year and next. SQZ Biotechnologies Co. raised $65 million in a...
BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms...
BioCentury | Mar 27, 2019
Financial News

Elicio raises $30M to target cancer vaccines to the lymph nodes

...KRAS - K-Ras Mary Romeo, Staff Writer Massachusetts Institute of Technology E6 transforming protein (Human papillomavirus-16) (HpV16gp1) E7 transforming protein (Human papillomavirus-16...
BioCentury | Jan 4, 2019
Financial News

Cellid proposes Korean IPO

...The company's lead product is BVAC-C, a B cell vaccine based on E6 transforming protein (human papillomavirus-16...
...Securities is underwriting the IPO. Cellid Co. Ltd., Seoul, South Korea Chris Lieu BVAC-C Cellid Inc. E6 transforming protein (Human papillomavirus-16...
BioCentury | Oct 31, 2018
Distillery Therapeutics

Cancer; infectious disease

...acute coronary syndrome, dyslipidemia, hypercholesterolemia, hyperlipidemia and to prevent cardiovascular events. TARGET/MARKER/PATHWAY: E7 transforming protein (Human papillomavirus-16...
...yanshi@biomed.tsinghua.edu.cn CONTACT: Yonghui Zhang, same affiliation as above email: zhangyonghui@tsinghua.edu.cn Mark Zipkin Zocor, simvastatin Tsinghua University E7 transforming protein (Human papillomavirus-16...
BioCentury | Sep 26, 2018
Distillery Therapeutics

Cancer

...therapy- or chemotherapy-resistant cancers. TARGET/MARKER/PATHWAY: ATP synthase peripheral stalk subunit d (ATP5H); E7 transforming protein (Human papillomavirus-16...
...Korea email: twkim0421@korea.com Sandi Wong Johns Hopkins University Korea University ATP synthase peripheral stalk subunit d (ATP5H) E7 transforming protein (Human papillomavirus-16...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Cancer

...solid tumors and HPV and Phase I/II testing for cervical cancer. TARGET/MARKER/PATHWAY: E7 transforming protein (Human papillomavirus-16...
...Lausanne (EPFL), Lausanne, Switzerland email: douglas.hanahan@epfl.ch Claire Quang Swiss Federal Institute of Technology Lausanne (EPFL) E7 transforming protein (Human papillomavirus-16...
BioCentury | Jul 13, 2018
Clinical News

Vaxart's teslexivir misses in Phase II for anogenital warts

...Calif. Product: Teslexivir (BTA074) Business: Infectious Molecular target: E1 protein (HPV-16; HpV16gp3) and E2 regulatory protein (HPV-16; HpV16gp4...
...to clearance Status: Phase II data Milestone: NA Elizabeth S. Eaton Teslexivir (ap611074, BTA074) Vaxart Inc. E1 protein (Human papillomavirus-16) (HpV16gp3) E2 regulatory protein (Human papillomavirus-16) (HpV16gp4)...
BioCentury | Jul 13, 2018
Clinical News

FDA lifts hold on Phase I/II of axalimogene filolisbac for SCCHN

...neck (SCCHN). Axalimogene filolisbac is a live Listeria monocytogenes -based immunotherapy expressing E7 transforming protein (human papillomavirus-16...
...Lovaxin C, ADXS-HPV) Business: Cancer Jaime De Leon Axalimogene filolisbac (ADXS11-001, adxs-hpv, lovaxin c) Advaxis Inc. E7 transforming protein (Human papillomavirus-16...
BioCentury | Jul 13, 2018
Clinical News

Advaxis rises after FDA lifts clinical hold

...neck (SCCHN). Axalimogene filolisbac is a live Listeria monocytogenes -based immunotherapy expressing E7 transforming protein (human papillomavirus-16...
...accelerated approval to treat urothelial carcinoma. Paul Bonanos Axalimogene filolisbac (ADXS11-001, adxs-hpv, lovaxin c) Advaxis Inc. E7 transforming protein (Human papillomavirus-16...
Items per page:
1 - 10 of 75